Vienna, March 16, 2020 On Wednesday March 11 the World Health Organization (WHO) announced a pandemic in response to the COVID-19 outbreak. This is a serious health situation influencing numerous countries worldwide. We want to...

more about "AOP Orphan Statement on SARS-CoV-2 and COVID-19"

BESREMi® is approved as first-line monotherapy in adults for the treatment of Polycythaemia vera (PV) without symptomatic splenomegaly BESREMi® showed high and durable hematologic response, molecular response and disease...

more about "AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV) "

AOP Orphan Pharmaceuticals AG, the Austrian specialist for rare diseases, will implement ‘Mobile IntelligenceTM (MI)’ - the smart CRM Tool from leading Life-Sciences consultant, IQVIA.

more about "AOP Orphan to implement innovative CRM system in collaboration with IQVIA Austria "

Bioprojet Pharma SAS and AOP Orphan Pharmaceuticals AG (AOP Orphan) entered a distribution agreement for Wakix®The covered territory includes mainly Central and Northern European countriesWakix® is approved for treatment of...

more about "AOP Orphan will distribute Wakix® (pitolisant) from Bioprojet Pharma SAS in Austria, Nordic countries and Central Eastern Europe (copy 1)"

AOP Orphan supports the Christian Doppler Laboratory for Iron Metabolism and Anemia Research at the Medical University of Innsbruck, Austria, opening on January 31st, 2018. To read the full press release in German, please click...

more about "The Medical University of Innsbruck: Christian Doppler Laboratory for Iron Metabolism and Anemia Research is opened."

AOP Orphan Pharmaceuticals AG announced today that it has acquired Selisistat, a highly selective SIRT1 inhibitor, which in experimental studies has previously shown potential disease modifying properties in a number of...

more about "AOP Orphan Pharmaceuticals AG to acquire Selisistat a clinical stage drug candidate for the treatment of Huntington’s disease (HD)"

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances,  which was published recently in...

more about "Austria as a Research & Development base"

Cancer Drug News 733

more about "AOP in Press: "New Therapies To Struggle Against Established Hematology""

Long-term maintenance treatment of Polycythemia Vera (PV) patients with Ropeginterferon alfa-2b administered every 4 weeks is feasible, efficacious and well toleratedHome self-administration of individual doses with a pen is well...

more about "AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid (copy 1)"

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that RAPIBLOC® (Rapibloc, 300 mg powder for solution for infusion) will as of June 19th be first commercialized by its distribution partner Amomed Pharma GmbH (Amomed)...

more about "AOP Orphan Pharmaceuticals AG and Amomed Pharma GmbH announce the launch of RAPIBLOC® (Landiolol) in Germany and Austria."

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about AOP Orphan’s commitment to sustainable innovation for the benefit of patients with rare diseases and Austria as a research location was published recently...

more about "Rare Diseases: AOP Orphan Pharmaceuticals AG invests in sustainable Research & Development"

Highlights: Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe.Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme...

more about "AOP Orphan Pharmaceuticals AG announces European “approvable” opinion of its ultra-short acting beta blocker Rapibloc® (Landiolol)"

As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts...

more about "Innovative antipsychotic ADASUVE® to benefit even more patients"

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®, developed by Cardiome Pharma Corp., Canada, in Central Europe....

more about "AOP Orphan to market the innovative antiarrhythmic drug BRINAVESS® exclusively in Central Europe"

The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...

more about "Internationally renowned pharmaceutical expert Hans Peter Hasler strengthens AOP Orphan Supervisory Board"

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.

more about "Partnership between AOP Orphan and Ferrer: Joint marketing of Adasuve® in CEE"

AOP Orphan announces progress of pan-European phase III trial PROUD-PV to support European Marketing Authorization of AOP2014/P1101, a next-generation, mono-pegylated Interferon alpha 2b.

more about "AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV of novel mono-pegylated Interferon alpha 2b for the treatment of Polycythemia vera"